Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 7/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8324137 | 0.92 | PRCP (0.33) | HRH4HRH3PRCPTDP1HRH1 | |
| SCHEMBL8318975 | 0.89 | HPGD (0.39) | PRCPTDP1NPC1RAB9A | |
| SCHEMBL8323902 | 0.87 | GRIN2B (0.40) | PTGS2PRCPTDP1 | |
| SCHEMBL8320315 | 0.86 | PRCP (0.37) | HRH3PRCPTDP1 | |
| SCHEMBL8323729 | 0.86 | PRCP (0.35) | PRCPTDP1RAB9A | |
| SCHEMBL8324904 | 0.86 | HRH3 (0.40) | HRH3PRCPNPC1 | |
| SCHEMBL8325059 | 0.85 | LMNA (0.36) | PRCPTDP1 | |
| SCHEMBL8318144 | 0.83 | KMT2A (0.35) | PRCPRAB9A | |
| SCHEMBL8321623 | 0.83 | GPBAR1 (0.40) | PRCP | |
| SCHEMBL8324737 | 0.83 | ALDH1A1 (0.31) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |